Beauty's prevailing narrative often frames skincare as a corrective response, something to consider only after visible aging sets in. DKGlow proposes a different theory, one that is embedded in the belief that maintenance, grounded in cellular science, should begin earlier and evolve with time.
Founded by Dr. Dorra Frikha, a PhD-trained scientist in bone mechanics, DKGlow is a biotech-driven skincare brand rooted in mitochondrial research. Frikha's doctoral work, she highlights, focused on mitochondrial osteocytes, bone cells, and the role of mitochondrial function in cell viability, particularly in estrogen-deficient, postmenopausal models. Her research explored how daily doses of FDA-approved methylene blue influenced oxidative stress and bone loss, forming the basis of a pending patent.
"Activating the mitochondria of your cells is the key," Frikha explains. "You are essentially triggering the cell's powerhouse to restore tissue on its own. The idea is to stimulate it so it functions optimally."
That cellular focus eventually migrated from bone biology to dermatology. During her laboratory research, Frikha observed how animals treated with methylene blue appeared to heal rapidly after surgery, with smoother skin and minimal visible scarring. The findings prompted a new line of exploration: could mitochondrial stimulation translate into a skincare strategy designed to support collagen production and tissue health at a deeper level?
"The reaction was notable," she recalls. "I saw how quickly recovery occurred, how smooth the skin became. It led me to ask how we could apply that same principle to human skin, without the need for invasive procedures."
DKGlow's product line centers largely on methylene blue-infused formulations, including facial serums, body serums, hair treatments, and sprays. The brand positions methylene blue as a compound capable of penetrating beyond the superficial layers of the skin, where it may support cellular energy processes linked to collagen production. Research validates the brand's perspective, as methylene blue has been linked to reducing age-related marks by stimulating elastin and collagen, improving skin thickness and hydration and potentially reducing photoaging.
Frikha frames her approach as one that works with the body's intrinsic mechanisms rather than delivering a short-lived aesthetic shift. Visible change, she emphasizes, requires consistency. "People are conditioned to expect immediate transformation," she says. "They want to leave the clinic with a new face that day. But if you commit to a protocol for a few weeks, you build something that lasts. You are maintaining your glow rather than chasing it."
The concept of early intervention is central to DKGlow's philosophy. Rather than targeting only individuals already experiencing pronounced signs of aging, the brand advocates beginning maintenance in one's late 20s or 30s. According to Frikha, proactive support of mitochondrial function may contribute to long-term skin resilience.
"You don't wait until bone loss is severe to think about prevention," she notes, drawing on her academic background. "The same logic applies to skin. Maintenance is always more effective than reversal."
Furthermore, DKGlow incorporates infrared technology into its portfolio. Infrared devices, Frikha highlights, share a complementary relationship with methylene blue by also stimulating mitochondrial pathways. "Infrared and methylene blue operate on similar biological principles. Together, they can amplify the effect because you are supporting cellular energy from two angles," she explains.
Frikha is also developing a concept she refers to as "blue aspirin," a low-dose combination of aspirin and methylene blue that remains in the patent and research phase. The formulation is envisioned as an over-the-counter, once-weekly maintenance pill for individuals over 50, pending further study and regulatory clarity. She frames it as a potential maintenance approach to cellular and circulatory support, though it still remains under development. She shares, "This is still visionary. My ambition is to collaborate with pharmaceutical partners who can help bring rigorous research and scale to the idea."
Investor engagement and strategic partnerships are part of DKGlow's next chapter. Frikha views biotech-skincare convergence as an emerging category, one that demands scientific credibility as much as consumer appeal.
Societal expectations, however, present a challenge. Frikha remarks that digital culture rewards immediacy, but biology does not. She believes reframing consumer timelines is essential to responsible growth in the category. "Technology has made everything instant," she reflects. "Skin does not work that way. If you give it the right ingredients and the right environment, it responds, but it responds on its own clock."
DKGlow's positioning rests on the premise that sustained mitochondrial support is a pathway to long-term skin vitality. Whether through serums, infrared integration, or future pharmaceutical collaborations, the brand's trajectory signals a broader shift toward preventative, science-led beauty, one cell at a time.
